Effects of combinational CYP3A5 6986A>G polymorphism in graft liver and native intestine on the pharmacokinetics of tacrolimus in liver transplant patients: a meta-analysis.
Many studies have reported reduced tacrolimus dose-adjusted exposure in individuals expressing the CYP3A5*1 allele. A meta-analyses of the current data may help characterize the extent of impact this polymorphism has on tacrolimus pharmacokinetics in adult liver transplant recipients and whether donor or recipient genotype is the most influential factor. Structured searches, of studies that evaluated the association between CYP3A5*1 allele and tacrolimus pharmacokinetics in adult liver transplant recipients, were conducted using Embase and Medline. A meta-analysis comparing tacrolimus daily dose, trough concentrations (C0), and dose-adjusted trough concentrations (C0/dose) across the donor and recipient genotype pairs was conducted using a random effects model. Eight studies, involving a total of 694 adult liver transplant recipients, were included. Dose-adjusted tacrolimus trough concentrations were significantly lower in those in whom the donor or recipient expressed a *1 allele compared with those in whom neither the donor nor recipient expressed this allele at 7 days and 2, 3, 6, and 12 months after transplant [standardized mean differences between expressers and nonexpressers of -1.98, -2.12, -2.39, -3.68, and -3.26 (ng/mL)/(mg·kg·d), respectively]. Results of the meta-analysis demonstrated that, in adult liver transplant patients, CYP3A5 expression in either the donor or recipient resulted in a need for a higher mean tacrolimus daily dose to achieve the target drug exposure. In the immediate posttransplant period, recipient expression of a CYP3A5*1 allele seemed to have the greatest influence on tacrolimus pharmacokinetics with donor expression of a CYP3A5*1 allelle possibly becoming more important with increasing time after transplant.